ArQule rises on renewed hope for twice-damned tivantinib – FierceBiotech

by lowes1 on September 28, 2013

ArQule rises on renewed hope for twice-damned tivantinib
FierceBiotech
ArQule ($ARQL) watched its shares scrape the bottom last fall when it pulled the plug on a late-stage lung cancer drug, but rumors that the Woburn, MA, company is primed to release data that could revive tivantinib sent its stock price up as much as 19
ArQule (ARQL) Tvantinib Has 'Good Chance' on Showing Benefit in MET-High StreetInsider.com (subscription)
ArQule, Inc. (ARQL): ArQule rallies on renewed hopes for tivantinibSeeking Alpha

all 4 news articles »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: